Meet one of our 2025 Short Term, High-Priority Grant Recipients, Katarzyna Taylor, PhD! With over a decade of experience in DM1 research, Dr. Katrarzyna Taylor has advanced therapeutic strategies using antisense oligonucleotides, small compounds, and drug repositioning. She has developed expertise in molecular techniques, bioinformatics, and therapeutic screening.

Dr. Taylor has published 13 articles and participated in major DM conferences. Her goal is to develop personalized combination therapies to improve treatment outcomes for DM patients. Her project “Identification of novel molecular mechanisms of MBNL1 expression as potential DM therapeutic targets” aims to identify novel regulatory elements controlling MBNL1 expression, expanding therapeutic targets and contributing to the development of personalized or combination therapies based on disease onset, progression, and individual patient response.

Click here to learn more about MDF's research funding opportunities and prior grant recipients.